share_log

T2 Biosystems | 144: Notice of proposed sale of securities pursuant to Rule 144

T2 Biosystems | 144: Notice of proposed sale of securities pursuant to Rule 144

T2 Biosystems | 144:拟议出售证券
美股SEC公告 ·  09/13 10:36

Moomoo AI 已提取核心信息

David B. Elsbree, a Director at T2 Biosystems, Inc., is set to sell 55 shares of the company's common stock with an aggregate market value of $132.5. The sale is scheduled for 09/13/2024. Elsbree acquired these shares through open market purchases and as compensation in the form of restricted stock units, with acquisition dates of 06/06/2017 and 06/25/2021, respectively. There have been no reported sales of securities by Elsbree in the past three months.
David B. Elsbree, a Director at T2 Biosystems, Inc., is set to sell 55 shares of the company's common stock with an aggregate market value of $132.5. The sale is scheduled for 09/13/2024. Elsbree acquired these shares through open market purchases and as compensation in the form of restricted stock units, with acquisition dates of 06/06/2017 and 06/25/2021, respectively. There have been no reported sales of securities by Elsbree in the past three months.
T2 Biosystems董事David b. Elsbree计划卖出公司55股普通股,总市值为132.5美元。该交易计划于2024年9月13日进行。Elsbree通过市场购买和限制性股票单位的补偿获得了这些股票,分别的获得日期为2017年6月6日和2021年6月25日。Elsbree过去三个月内没有报告出售证券。
T2 Biosystems董事David b. Elsbree计划卖出公司55股普通股,总市值为132.5美元。该交易计划于2024年9月13日进行。Elsbree通过市场购买和限制性股票单位的补偿获得了这些股票,分别的获得日期为2017年6月6日和2021年6月25日。Elsbree过去三个月内没有报告出售证券。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息